Pharmafile Logo
Pharmafocus logo
Advanced Search

GlaxoSmithKline

Showing 15 posts of 164 posts found.

GSK paves way for biopharmaceuticals growth

September 9, 2010
Research and Development GlaxoSmithKline, Lonza, biologics

GlaxoSmithKline has handed Swiss contract manufacturer Lonza a contract to produce clinical trial batches of five monoclonal antibodies that are …

News

Pressure mounts on GSK over Avandia

September 6, 2010
Sales and Marketing Avandia, GlaxoSmithKline

GlaxoSmithKline is under mounting pressure this week as calls intensify for its type II diabetes drug Avandia to be withdrawn …

News
Pandemrix pack

EMA to assess GSK flu vaccine for narcolepsy link

September 1, 2010
Research and Development, Sales and Marketing GlaxoSmithKline, Pandemrix, h1n1

The European Medicines Agency has launched a review of GlaxoSmithKline’s influenza vaccine Pandemrix. The European Commission asked the EMA to …

News

A revolution for the NHS – an opportunity for pharma?

August 9, 2010
Sales and Marketing GlaxoSmithKline, NHS

Healthcare systems across western Europe are currently under renewed pressure and scrutiny, each government preoccupied with finding major cost-savings to …

Feature

GSK’s Arixtra set for expanded licence

July 26, 2010
Sales and Marketing Arixtra, Avandia, GlaxoSmithKline, rotarix

GlaxoSmithKline is set to receive a green light to use its anti-clotting drug Arixtra to prevent spontaneous superficial-vein thrombosis (SVT). …

News

Legal costs dent GlaxoSmithKline’s Q2

July 22, 2010
Medical Communications, Sales and Marketing 2010 financials, GlaxoSmithKline, Q2

GSK has reported a loss for its second quarter due to litigation costs related to Avandia and other problems. In …

News

GSK takes £1.58bn hit from legal disputes

July 16, 2010
Sales and Marketing Avandia, GlaxoSmithKline, Paxcil, Seroxat

GlaxoSmithKline is set to pay £1.58 billion to settle three long-standing legal disputes, including litigation costs for its troubled diabetes …

News
Avandia

GSK accused of Avandia cover-up

July 14, 2010
Sales and Marketing Avandia, GlaxoSmithKline, diabetes

The ongoing battle over GlaxoSmithKline’s diabetes drug Avandia has taken another turn with US senators accusing the company of a …

News
Avastin packshot

Avandia to face European safety review

July 12, 2010
Sales and Marketing Avandia, GlaxoSmithKline, diabetes

GlaxoSmithKline’s type II diabetes drug Avandia, the subject of safety concerns since its launch in 2000, is to be reviewed …

News
GSK workers protest

Aptuit deal saves GSK’s R&D unit in Verona

July 5, 2010
Manufacturing and Production, Research and Development Aptuit, GlaxoSmithKline, Italy

GlaxoSmithKline has sold off its medicines research facility in Verona, Italy, to contract research and manufacturing service group Aptuit in …

News
Duncan-Learmouth

Duncan Learmouth to lead new GSK unit

July 5, 2010
Sales and Marketing GlaxoSmithKline, appointment, em, market access, sales and marketing

GlaxoSmithKline has created a new business group dedicated to improving access to medicines in the world’s least developed countries. GSK’s …

Appointment
Avandia

Avandia probe deepens

June 29, 2010
Sales and Marketing Avandia, GlaxoSmithKline, diabetes

GlaxoSmithKline has come under further scrutiny from the FDA after two new studies showed patients taking its troubled diabetes medication …

News

Prosensa and GSK add to muscular dystrophy alliance

June 23, 2010
Research and Development GlaxoSmithKline, Prosensa, muscular dystrophy

GSK has extended its research alliance with biotech company Prosensa in the field of muscular dystrophy. Netherlands-based Prosensa focuses on …

News

GSK tops access to medicines ranking

June 21, 2010
Sales and Marketing GlaxoSmithKline, developing world, medicines access

GlaxoSmithKline does the most of any pharma manufacturer to improve access to medicines needed in the developing world, according to …

News

GSK’s Votrient approved in Europe

June 16, 2010
Sales and Marketing GlaxoSmithKline, Kidney cancer, Votrient

The European Commission has granted a conditional marketing authorisation for a GlaxoSmithKline drug that treats the most common form of …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026